Navigating a Patent Cliff with a Reshaped Innovative Portfolio

Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, operating in over 140 countries with approximately 76,000 employees. Following the 2023 spin-off of Sandoz, the company is singularly focused on innovative medicines across four therapeutic areas: oncology (33% of sales), immunology (22%), cardiovascular/renal/metabolic (19%), and neuroscience (12%).

The company's revenue model centers on patented prescription drugs, with its top-selling products including Entresto (heart failure, $6B annual sales), Cosentyx (psoriasis/ankylosing spondylitis, ~$5B), Kisqali (breast cancer, ~$2.5B and rapidly growing), and Pluvicto ($1.5B and accelerating). Novartis also generates revenue from its generics division (now divested), royalties, and a modest diagnostics portfolio.

Scale is significant: with $264.4B market capitalization and 1,900.71M shares outstanding, Novartis ranks among the top five global pharmaceutical companies by value. The public float of 1,856.35M shares provides deep liquidity, while the 0.49 beta confirms its defensive, non-cyclical demand profile.

• Near-Term (2024-2026): Revenue growth is expected to remain relatively flat to low-single-digit as Entresto and Cosentyx lose U.S. exclusivity (2025-2026). However, Kisqali's adjuvant indication expansion, Pluvicto's continued uptake in earlier lines of therapy, and Leqvio's launch trajectory should offset roughly 60-70% of the patent cliff impact. Management guides for mid-single-digit core operating income growth during this period.
• Medium-Term (2027-2028): The company anticipates a return to 5%+ revenue growth as new molecular entities mature. Key catalysts include: (1) Pluvicto moving into hormone-sensitive prostate cancer (a 3-4x larger addressable population), (2) the oral complement inhibitor iptacopan (PNH and IgA nephropathy) with peak sales potential exceeding $3B, (3) remibrutinib in chronic spontaneous urticaria, and (4) a broad radioligand pipeline with 10+ candidates in development.
• Pipeline Depth: With 25+ Phase 3 assets and 30+ Phase 2 assets, Novartis has one of the industry's deepest pipelines. The company targets 20+ new drug submissions by 2028, with a particular emphasis on first-in-class mechanisms that command premium pricing.

Note: 2022-2023 figures reflect continuing operations (ex-Sandoz). 2024-2026 are analyst consensus estimates.

The 2023 revenue decline reflects the Sandoz divestiture, while 2024's recovery demonstrates the underlying growth of the innovative portfolio. Core operating margin expansion — from 36.8% to over 40% — is driven by productivity programs and a richer product mix as lower-margin generics were removed. The dip in 2025E earnings reflects the U.S. patent cliff for Entresto, partially mitigated by cost discipline. Free cash flow conversion remains strong at ~85-90% of net income, supporting the company's capital return program.

The global pharmaceutical market is valued at approximately $1.6 trillion, growing at 4-6% annually. Within Novartis's core therapeutic areas, the oncology market ($250B) and immunology market ($150B) represent the largest opportunities. The radioligand therapy segment, where Novartis leads, is projected to grow from ~$2B today to $30B+ by 2030, driven by precision medicine trends and the ability to treat metastatic cancers with targeted radiation.

Novartis's competitive positioning is differentiated by its technological platform in radioligand therapy — a modality with no direct large-cap competitor at similar scale. However, the company faces intense competition in its core oncology and immunology franchises from PD-1 inhibitors (Merck, BMS), JAK inhibitors (Pfizer, AbbVie), and emerging bispecific antibodies. The company's relative valuation discount (approximately 10-15% below peer average forward P/E) reflects this competitive intensity and the patent cliff overhang.

Discounted Cash Flow Analysis: Applying a WACC of 7.5% (reflecting low beta of 0.49, Swiss risk-free rate of ~0.8%, and an equity risk premium of 5.5%) and a terminal growth rate of 2.0%, our base-case DCF — assuming 3% average revenue growth through 2033, a 40% core operating margin, and a 22% effective tax rate — yields an intrinsic value of approximately $158 per share. This implies the current price of $139.85 represents a ~12% discount to intrinsic value, offering a margin of safety.

Comparable Company Analysis:

Novartis trades at a premium to its large-cap peers on earnings multiples, which appears inconsistent with its patent cliff exposure — suggesting the market is pricing in successful pipeline execution. However, the stock's defensive characteristics (low beta, high dividend, strong balance sheet) warrant a modest premium. On a risk-adjusted basis, the stock appears fairly valued with limited upside absent positive pipeline news flow.

• Accelerated Biosimilar Erosion: Entresto faces U.S. patent expiry in 2025, and while regulatory exclusivity extends to 2026, aggressive biosimilar entry could accelerate revenue decline beyond current consensus expectations. A 20% faster-than-expected erosion would reduce 2026 EPS by approximately $0.30-0.40.
• Pluvicto Supply Constraints: The radioligand therapy requires specialized manufacturing facilities with limited global capacity. Any production disruption or regulatory compliance issue at Novartis's Indianapolis or Zaragoza plants could severely impact the company's highest-growth product, with potential revenue impact of $500M+ per quarter.
• Regulatory and Pricing Pressure: U.S. Inflation Reduction Act drug price negotiations will impact several Novartis products (Entresto is among the first 10 drugs selected for Medicare negotiation). European pricing reforms and international reference pricing could compress margins by 100-200 basis points across the portfolio by 2028.
• Clinical Trial Failures: With 25+ Phase 3 assets, the probability of at least one high-profile failure is significant. A negative readout for iptacopan in IgA nephropathy or remibrutinib in chronic spontaneous urticaria would remove $3-5B of peak sales potential and undermine the growth narrative.
• Integration and Execution Risk: The company's aggressive M&A strategy (recent acquisitions of Chinook Therapeutics, MorphoSys, and Mariana Oncology for a combined ~$10B) carries integration risk. Overpaying for pipeline assets or failing to capture synergies could dilute shareholder value.